An observational study in Cerebral Ischemia, sponsored by Xi'an No.3 Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-09-01.
Sponsored by Xi'an No.3 Hospital · Observational
This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.
Ischemic cerebrovascular disease is an important cause of death and disability in the world. Digital Subtraction Angiography (DSA) is the golden index for evaluating cerebral blood vessels. We introduced a new parameter derived from DSA to evaluate the perfusion to predict the outcomes in acute stroke with large vessel occlusion.
To study the possible relationship between the new parameter of cerebral perfusion derived from DSA and outcomes in cerebral ischemia（modified Rankin Scale）, we intend to retrospectively analyze the images derived from patients who undergone the DSA and follow-up outcomes（modified Rankin Scale）.
217 studies on the registry are indexed under Brain Ischemia; 42 are open to participants now.
This study's planned enrollment of 30,000 is above the median of 203 across 72 observational studies indexed under Brain Ischemia.
Browse Brain Ischemia studies →Xi'an No.3 Hospital is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
the study population is from primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1.cerebral hemorrhage
We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(good perfusion)
We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(middle perfusion)
We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(poor perfusion)
the outcomes between good perfusions and poor perfusions
Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).
Time frame: 3 months to 2 years
the outcomes between good perfusions and middle perfusions
Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).
Time frame: 3 months to 2 years
Started Jul 2018 (actual). Primary completion is estimated for Jul 2028, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xi'an No.3 Hospital